ArticleNature2021
Functional HPV-specific PD-1
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 243 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
243citing papers in PubMed, 1 pooled it
23.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
243 citing papers in PubMed, 1 synthesis or guideline pooled it, 334 citations in OpenAlex.
- Immunological and antitumor responses to HPV-targeted therapeutic vaccines in preclinical models of head and neck cancer: a systematic review.Cancer metastasis reviews · 2026Pooled it
- Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial.American journal of clinical oncology · 2026Trial
- Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.Cancer discovery · 2025Trial
- Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab.Cancer immunology, immunotherapy : CII · 2025Trial
- DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.Nature communications · 2025Trial
- Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Trial
- Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.Nature medicine · 2023Trial
- Efineptakin alfa (NT-I7) improves overall survival and induces immune niches in murine tumors.Genes & diseases · 2027Article
- The LXRβ/NF-κB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment.Oncoimmunology · 2026Article
- Characterization of persistent HPV-specific activated T cells in head and neck squamous cell carcinoma.Oncoimmunology · 2026Article
- Article
- Viral persistence and host-state remodeling in virus-associated cancers.Archives of microbiology · 2026Review
- Article
- Review
- Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026Review
- New insights into progenitor exhausted T cell populations.Nature reviews. Immunology · 2026Article
- Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancer.Nature communications · 2026Article
- Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation.Vaccines · 2026Review
- Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations.Health science reports · 2026Article
- Response of B Cells Specific for Polyomavirus-Derived Oncoprotein Is Predictive of Merkel Cell Carcinoma Tumor Control.Cancer immunology research · 2026Article
183 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 6 institutions in 3 countries.
Christiane S Eberhardt *Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Haydn T Kissick *Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7624-5598
Mihir R PatelWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Maria A CardenasDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Nataliya ProkhnevskaDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Rebecca C ObengEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8624-7108
Tahseen H NastiEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Christopher C GriffithWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Se Jin ImEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Xu WangDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Dong M ShinDivision of General Pediatrics, Department of Pediatrics, Gynecology & Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Mary CarringtonBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2692-2180
Zhuo G ChenWinship Cancer Institute of Emory University, Atlanta, GA, USA.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.
Nabil F SabaWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Andreas WielandEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA. andreas.wieland@emory.edu.ORCID http://orcid.org/0000-0001-9648-7922
Rafi AhmedEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA. rahmed@emory.edu.ORCID http://orcid.org/0000-0002-9591-2621
Emory University · USLa Jolla Institute for Immunology · USUniversity of Geneva · CHEmory Healthcare · USNorthwestern University · USRagon Institute of MGH, MIT and Harvard · US
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MImplementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1MVACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7MWinship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MMolecular genetics and population studies of the KIR and HLA gene complexesZ01BC010792 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2007 to 2008
$1.0MCCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 BC010792NCATS NIH HHS UL1 TR002378NCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA138292NIAID NIH HHS P01 AI056299NIAID NIH HHS U19 AI057266NIH HHS 2P30 CA138292-04NIH HHS P51 OD011132
Abstract
T cells are important in tumour immunity but a better understanding is needed of the differentiation of antigen-specific T cells in human cancer
Indexed as
AlphapapillomavirusCancer VaccinesCD8-Positive T-LymphocytesCell DifferentiationCell ProliferationDNA-Binding ProteinsHead and Neck NeoplasmsHumansLymphocytes, Tumor-InfiltratingOncogene Proteins, ViralPapillomavirus InfectionsPapillomavirus VaccinesProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellRNA-SeqSingle-Cell AnalysisCancer VaccinesDNA-Binding ProteinsE2 protein, Human papillomavirus type 16oncogene protein E5, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus VaccinesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellT Cell Transcription Factor 1TCF7 protein, humanViroporin Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.